Document is current
Any future updates will be listed below
-
Authors
Pinto, Thatiana https://orcid.org/0000-0002-0957-3118
Kocaata, Zeki https://orcid.org/0000-0002-5231-3389
Medina, Ana https://orcid.org/0000-0001-8216-2350
Sampietri, Igor https://orcid.org/0009-0000-1557-7062
Bernardino, Graziela https://orcid.org/0000-0002-8117-4648
Zawieja, Justyna https://orcid.org/0009-0006-9759-1960
Gil-Rojas, Yaneth https://orcid.org/0000-0002-9908-4878
Tytuła, Anna https://orcid.org/0009-0004-8827-1469
Graña, Maria Gabriela https://orcid.org/0000-0001-9577-4428
Kuylen, Elise https://orcid.org/0000-0002-3528-5507
-
Funding
Funding for this research was provided by:
GlaxoSmithKline Biologicals (VEO-000961)
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 13 February 2026
First Online: 8 April 2026
Declarations
:
: Thatiana Pinto, Elise Kuylen, Ana Medina, Igor Sampietri, Graziela Bernardino, Maria Gabriela Graña and Zeki Kocaata are employed by and hold financial equities in GSK. Justyna Zawieja, Yaneth Gil-Rojas and Anna Tytuła are employees of Putnam, who received funding from GSK for this study. The authors disclose no other financial and non-financial relationships and activities.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
